Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
KERX's Cash to Debt is ranked higher than
95% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. KERX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
KERX' s 10-Year Cash to Debt Range
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6484
N/A
No Debt
Equity to Asset 0.82
KERX's Equity to Asset is ranked higher than
69% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. KERX: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
KERX' s 10-Year Equity to Asset Range
Min: -0.06  Med: 0.83 Max: 0.93
Current: 0.82
-0.06
0.93
Interest Coverage No Debt
KERX's Interest Coverage is ranked higher than
91% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. KERX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
KERX' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: 8.37
M-Score: 23.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -6270.10
KERX's Operating margin (%) is ranked lower than
90% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. KERX: -6270.10 )
Ranked among companies with meaningful Operating margin (%) only.
KERX' s 10-Year Operating margin (%) Range
Min: -15010.67  Med: -3978.25 Max: 38.97
Current: -6270.1
-15010.67
38.97
Net-margin (%) -6286.35
KERX's Net-margin (%) is ranked lower than
90% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. KERX: -6286.35 )
Ranked among companies with meaningful Net-margin (%) only.
KERX' s 10-Year Net-margin (%) Range
Min: -13813.48  Med: -4072.06 Max: 41.62
Current: -6286.35
-13813.48
41.62
ROE (%) -103.23
KERX's ROE (%) is ranked lower than
81% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. KERX: -103.23 )
Ranked among companies with meaningful ROE (%) only.
KERX' s 10-Year ROE (%) Range
Min: -429.23  Med: -81.24 Max: 68.51
Current: -103.23
-429.23
68.51
ROA (%) -85.01
KERX's ROA (%) is ranked lower than
82% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. KERX: -85.01 )
Ranked among companies with meaningful ROA (%) only.
KERX' s 10-Year ROA (%) Range
Min: -323.38  Med: -66.67 Max: 31.09
Current: -85.01
-323.38
31.09
ROC (Joel Greenblatt) (%) -10562.84
KERX's ROC (Joel Greenblatt) (%) is ranked lower than
88% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. KERX: -10562.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KERX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -46369.35  Med: -4919.08 Max: 7114.49
Current: -10562.84
-46369.35
7114.49
Revenue Growth (3Y)(%) 19.70
KERX's Revenue Growth (3Y)(%) is ranked higher than
78% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. KERX: 19.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
KERX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -50.00 Max: 268.4
Current: 19.7
0
268.4
EBITDA Growth (3Y)(%) 41.60
KERX's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. KERX: 41.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
KERX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45.1  Med: 16.55 Max: 71.3
Current: 41.6
-45.1
71.3
EPS Growth (3Y)(%) 43.10
KERX's EPS Growth (3Y)(%) is ranked higher than
90% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. KERX: 43.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
KERX' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.5  Med: 15.90 Max: 60
Current: 43.1
-44.5
60
» KERX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

KERX Guru Trades in Q2 2014

Seth Klarman 10,539,986 sh (+67.01%)
Seth Klarman 9,151,600 sh (+45.01%)
Steven Cohen 1,247,000 sh (unchged)
Pioneer Investments Sold Out
Jim Simons Sold Out
» More
Q3 2014

KERX Guru Trades in Q3 2014

Seth Klarman 18,300,000 sh (+73.62%)
Seth Klarman 18,300,000 sh (+73.62%)
Steven Cohen Sold Out
» More
Q4 2014

KERX Guru Trades in Q4 2014

Seth Klarman 18,300,000 sh (unchged)
» More
Q1 2015

KERX Guru Trades in Q1 2015

Seth Klarman 22,380,200 sh (+22.30%)
» More
» Details

Insider Trades

Latest Guru Trades with KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Keryx Biopharmaceuticals Inc

Baupost’s Seth Klarman Buys Cheniere Energy, Ocwen Financial, Antero Resources, Sells Boyd Gaming, Theravance
Renowned value investor, hedge fund manager Seth Klarman (Trades, Portfolio) just reported his third quarter portfolio. Seth Klarman (Trades, Portfolio) buys Cheniere Energy Inc, Ocwen Financial Corp, Antero Resources Corp, Veritiv Corp, Keryx Biopharmaceuticals Inc, eBay Inc, PBF Energy Inc, Forward Pharma AS, PBF Energy Inc, Atara Biotherapeutics Inc, sells Boyd Gaming Corporation, Theravance Inc, Syneron Medical Ltd during the 3-months ended 09/30/2014, according to the most recent filings of his investment company, The Baupost Group. As of 09/30/2014, The Baupost Group owns 27 stocks with a total value of $5.7 billion. These are the details of the buys and sells. Read more...
Seth Klarman’s The Baupost Group Buys eBay, SunEdison Semiconductor, Keryx Biopharmaceuticals, Sells BP, Theravance
Legendary value investor, hedge fund manager Seth Klarman (Trades, Portfolio) just reported his second quarter portfolio. Seth Klarman (Trades, Portfolio) buys eBay Inc, SunEdison Semiconductor Ltd, Keryx Biopharmaceuticals Inc, Kosmos Energy Ltd, Boyd Gaming Corporation, Triquint Semiconductor, RF Micro Devices Inc, Cheniere Energy Inc, Viasat Inc, Veritiv Corp, Veritiv Corp, sells BP PLC, Theravance Inc during the 3-months ended 06/30/2014, according to the most recent filings of his investment company, The Baupost Group. As of 06/30/2014, The Baupost Group owns 24 stocks with a total value of $6.1 billion. These are the details of the buys and sells. Read more...

Ratios

vs
industry
vs
history
Forward P/E 31.15
KERX's Forward P/E is ranked lower than
64% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. KERX: 31.15 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 4.90
KERX's P/B is ranked lower than
52% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. KERX: 4.90 )
Ranked among companies with meaningful P/B only.
KERX' s 10-Year P/B Range
Min: 1.88  Med: 7.14 Max: 49
Current: 4.9
1.88
49
P/S 399.00
KERX's P/S is ranked lower than
94% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. KERX: 399.00 )
Ranked among companies with meaningful P/S only.
KERX' s 10-Year P/S Range
Min: 1.1  Med: 97.91 Max: 1911
Current: 399
1.1
1911
Current Ratio 5.52
KERX's Current Ratio is ranked higher than
57% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. KERX: 5.52 )
Ranked among companies with meaningful Current Ratio only.
KERX' s 10-Year Current Ratio Range
Min: 1.88  Med: 7.62 Max: 106.93
Current: 5.52
1.88
106.93
Quick Ratio 4.77
KERX's Quick Ratio is ranked higher than
55% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. KERX: 4.77 )
Ranked among companies with meaningful Quick Ratio only.
KERX' s 10-Year Quick Ratio Range
Min: 1.88  Med: 7.62 Max: 106.93
Current: 4.77
1.88
106.93
Days Inventory 2.00
KERX's Days Inventory is ranked higher than
95% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 118.28 vs. KERX: 2.00 )
Ranked among companies with meaningful Days Inventory only.
KERX' s 10-Year Days Inventory Range
Min: 2886.82  Med: 2886.82 Max: 2886.82
Current: 2
Days Sales Outstanding 234.15
KERX's Days Sales Outstanding is ranked lower than
92% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. KERX: 234.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
KERX' s 10-Year Days Sales Outstanding Range
Min: 0.51  Med: 63.30 Max: 2248.5
Current: 234.15
0.51
2248.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.28
KERX's Price/Net Cash is ranked higher than
60% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. KERX: 6.28 )
Ranked among companies with meaningful Price/Net Cash only.
KERX' s 10-Year Price/Net Cash Range
Min: 1.09  Med: 7.31 Max: 29.11
Current: 6.28
1.09
29.11
Price/Net Current Asset Value 5.05
KERX's Price/Net Current Asset Value is ranked higher than
64% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. KERX: 5.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KERX' s 10-Year Price/Net Current Asset Value Range
Min: 1.07  Med: 7.20 Max: 26.2
Current: 5.05
1.07
26.2
Price/Tangible Book 4.99
KERX's Price/Tangible Book is ranked higher than
55% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. KERX: 4.99 )
Ranked among companies with meaningful Price/Tangible Book only.
KERX' s 10-Year Price/Tangible Book Range
Min: 0.93  Med: 6.23 Max: 26.2
Current: 4.99
0.93
26.2
Price/Median PS Value 4.11
KERX's Price/Median PS Value is ranked lower than
90% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. KERX: 4.11 )
Ranked among companies with meaningful Price/Median PS Value only.
KERX' s 10-Year Price/Median PS Value Range
Min: 0.01  Med: 1.22 Max: 19.7
Current: 4.11
0.01
19.7
Earnings Yield (Greenblatt) (%) -19.80
KERX's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. KERX: -19.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KERX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.8  Med: 178.65 Max: 27616.5
Current: -19.8
1.8
27616.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:KYX.Germany,
Keryx Biopharmaceuticals Inc was incorporated in Delaware in October 1998. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease. It is developing ZerenexTM an oral, ferric iron-based compound. It has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease, or CKD, on dialysis, conducted pursuant to a Special Protocol Assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA. Its New Drug Application, or NDA, is currently under review by the FDA with an assigned Prescription Drug User Fee Act, or PDUFA. It has also completed a U.S.-based Phase 2 study of Zerenex for the management of elevated serum phosphorus levels and iron deficiency anemia in subjects with Stage 3 to 5 NDD-CKD. Currently, its only drug candidate is Zerenex. Its competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions.
» More Articles for KERX

Headlines

Articles On GuruFocus.com
main Jul 01 2015 
main Jul 01 2015 
Is Seth Klarman right about Keryx Inc.? Jun 25 2015 
Seth Klarman Buys Pioneer Natural Resources, SunEdison Semiconductor Ltd, Atara Biotherapeutics Inc, May 15 2015 
my portfolio May 08 2015 
Analysts Positive on Keryx Biopharmaceuticals, Inc. Despite Weak Prescription Data May 05 2015 
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
Portfolio Feb 16 2015 
2015 Must-Buys In Biotech Sector Feb 02 2015 
me Jan 23 2015 

More From Other Websites
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2015 Financial Results on... Jul 28 2015
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2015 Financial Results on... Jul 28 2015
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jul 27 2015
Keryx Biopharmaceuticals Appoints Scott A. Holmes as Chief Financial Officer Jul 27 2015
Keryx Biopharmaceuticals Appoints Scott A. Holmes as Chief Financial Officer Jul 27 2015
Keryx Receives CHMP Positive Opinion for Fexeric(R) (Ferric Citrate Coordination Complex) for the... Jul 24 2015
Keryx Receives CHMP Positive Opinion for Fexeric(R) (Ferric Citrate Coordination Complex) for the... Jul 24 2015
Faruqi & Faruqi, LLP is Investigating Keryx Biopharmaceuticals, Inc. (KERX) on Behalf of its... Jul 16 2015
Blame Keryx Executives, Not Short Sellers, for Dismal Drug Launch, Sinking Stock Jul 07 2015
Edited Transcript of KERX presentation 24-Jun-15 6:30pm GMT Jun 29 2015
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 24 2015
​Boston drug company Keryx continues to shake off the haters Jun 24 2015
Keryx Announces Two National Insurance Providers Added Auryxia(TM) to Their Medicare Part D... Jun 24 2015
Keryx Announces Two National Insurance Providers Added Auryxia(TM) to Their Medicare Part D... Jun 24 2015
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 17 2015
Keryx Biopharmaceuticals to Present at the JMP Securities Life Sciences Conference 2015 Jun 16 2015
Keryx Biopharmaceuticals to Present at the JMP Securities Life Sciences Conference 2015 Jun 16 2015
MKM Partners' 4 Health Care Stocks to Sell Before June May 27 2015
Billionaire Klarman’s Top Small-Cap Picks: ViaSat Inc., Theravance Inc., PBF Energy May 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK